DOI: https://doi.org/10.22263/2312-4156.2017.2.70
Bubeshka D.A., Snezhitskiy V.A., Stepuro T.L.
The relationship of interleukin-10 gene polymorphism C-592A with interleukin-10 level and the risk of nonvalvular atrial fibrillation development
Grodno State Medical University, Grodno, Republic of Belarus
Vestnik VGMU. 2017;16(2):70-78.
Abstract.
Objectives. To study the distribution of genotypes and alleles frequencies of the polymorphic marker С-592А of interleukin-10 (IL-10) gene and to evaluate the relationship of the mentioned polymorphism with IL-10 plasma levels in patients of Grodno region with nonvalvular atrial fibrillation (AF) with ischemic heart disease (IHD) and/or arterial hypertension (AH), with ischemic heart disease and/or AH without the history of AF episodes and in patients without any cardiovascular diseases.
Material and methods. 105 patients with ischemic heart disease and/or arterial hypertension were examined. Among them there were 74 patients with persistent and permanent atrial fibrillation and 31 patients without AF episodes in their history. The control group included 37 patients without cardiovascular diseases and AF. IL-10 blood plasma levels were evaluated by ELISA test. The identification of polymorphism С-592А of IL-10 gene was performed using the polymerase chain reaction.
Results. It has been revealed that in the group of patients with AF the frequency of АА genotype and А allele was significantly higher than that in the group of patients with ischemic heart disease and/or arterial hypertension without AF episodes in their history f and also than that in the group of patients without any cardiovascular pathology. Nucleotide polymorphism association with the IL-10 level in plasma was revealed only in patients with AF and left ventricular systolic dysfunction. The maximum level of IL-10 was observed in patients with CC/CA genotype and C allele.
Conclusions. The presence of A allele in the genotype is associated with the 1,34-fold increase of nonvalvular AF development risk (95% CI 1,14-1,56), while the presence of AA genotype 1,48 times increases the risk of this disease development (95% CI 1,3-1,71) in patients with ischemic heart disease and/or arterial hypertension.
Key words: atrial fibrillation, interleukin -10, polymorphism С-592А.
References
1. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015 Jul;386(9989):154-62. doi: http://dx.doi.org/10.1016/S0140-6736(14)61774-8
2. Snezhitskiy VA, Bubeshko DA. The role of inflammation in pathogenesis of atrial fibrillation. Kardiologiia Belarusi. 2015;41(4):129-38. (In Russ.)
3. Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A, et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J Am Coll Cardiol. 2010 Aug;56(10):789-95. doi: http://dx.doi.org/10.1016/j.jacc.2010.02.066
4. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J. 2004 Sep;148(3):462-6. doi: http://dx.doi.org/10.1016/j.ahj.2004.01.026
5. Itoh K, Hirohata S. The role of IL-10 in human В cell activation, proliferation and differentiation. J Immunol. 1995 May;154(9):4341-50.
6. Heeschen C, Demeter S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 2003 Apr;107(16):2109-14. doi: http://dx.doi.org/10.1161/01.CIR.0000065232.57371.25
7. Pasqui AL, Di Renzo M, Maffei S, Pastorelli M, Pompella G, Auteri A, et al. Pro/Anti-inflammatory cytokine imbalance in postischemic left ventricular remodeling. Mediators Inflamm. 2010;2010:974694. doi: http://dx.doi.org/10.1155/2010/974694
8. Cavusoglu E, Marmur JD, Hojjati MR, Chopra V, Butala M, Subnani R, et al. Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. Am J Med. 2011 Aug;124(8):724-30. doi: http://dx.doi.org/10.1016/j.amjmed.2011.02.040
9. Amir O, Rogowski O, David M, Lahat N, Wolff R, Lewis BS. Circulating interleukin-10: association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha. Isr Med Assoc J. 2010 Mar;12(3):158-62.
10. Berns SA, Shmidt EA, Makeeva OA, Golikova AA, Ivanova TB, Nagirnyak OA, i dr. The relationship of loci polymorphisms g-1082a and c-592a IL10 gene with multifocal atherosclerosis in patients with acute coronary syndrome without ST-segment elevation. Klin Meditsina. 2015;93(11):28-34. (In Russ.)
11. Scarpelli D, Cardellini M, Andreozzi F, Laratta E, Hribal ML, Marini MA, et al. Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in caucasian italian subjects. Diabetes. 2006 May;55(5):1529-33.
12. Lowe PR, Galley HF, Abdel-Fattah A, Webster NR. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med. 2003 Jan;31(1):34-8.
13. Zheng DD, Ji SN, Chen C, Deng XT, Su YM, Pan HY, et al. Association of Interleukin-10 promotor polymorphisms with atrial fibrillation in Han Chinese. Int J Clin Exp Med. 2014;7(11):4199-206.
14. Reuses E, Fimmers R, Kruger A, Becker C, Rittner C, Höhler T. Differential regulation of interleukin-10 production by genetic and environmental factors – a twin study. Genes Immun. 2002 Nov;3(7):407-13. doi: http://dx.doi.org/10.1038/sj.gene.6363920
15. Eder T, Mayer R, Langsenlehner U, Renner W, Krippl P, Wascher TC, et al. Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study. Eur J Cancer. 2007 Feb;43(3):472-5. doi: http://dx.doi.org/10.1016/j.ejca.2006.11.003
16. Kato K, Oguri M, Hibino T, Yajima K, Matsuo H, Segawa T, et al. Genetic factors for lone atrial fibrillation. Int J Mol Med. 2007 Jun;19(6):933-9.
Information about authors:
Bubeshka D.A. – postgraduate of the Chair of Internal Medicine No.1, Grodno State Medical University;
Snezhitskiy V.A. – Doctor of Medical Sciences, corresponding member of the Belarusian National Academy of Sciences, rector, professor of the Chair of Internal Medicine No.1, Grodno State Medical University;
Stepuro T.L. – associate research officer of the Scientific-Research Laboratory of the Scientific-Research Department, Grodno State Medical University.
Correspondence address: Republic of Belarus, 230009, Grodno, 80 Gorky str., Grodno State Medical University, Chair of Internal Medicine No.1. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Darya A. Bubeshka.
